logo-loader
viewArix Bioscience PLC

Notice of Annual Results

/**/ p{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .aq{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.aq{}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 19.5pt; margin-bottom: 15.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; text-align: center}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;text-align:justify}p.bg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.ba{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 18.0pt; margin-right: 0cm; margin-top: 0cm; text-align: center}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 18.0pt; margin-right: 0cm; margin-top: 0cm; text-align: justify}p.bj{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none; font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.ax{font-size:11.0pt;font-family:"Calibri","sans-serif"} p.bk{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; background:white}span.bl{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.bm{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; background:white}span.bn{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bo{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;margin:0cm;margin-bottom:.0001pt;text-align:justify; background:white}p.bp{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;margin:0cm;margin-bottom:.0001pt;text-align:justify; background:white}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify} /**/
RNS Number : 9492K
Arix Bioscience Plc
16 April 2018
 

Notice of Annual Results and analyst briefing

LONDON, 16 April, 2018: Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its annual results for the period ended 31 December 2017 on Monday 23 April 2018.

Joe Anderson, Chief Executive Officer, and James Rawlingson, Chief Financial Officer, will host a lunch briefing and call for analysts at 12:00 BST on the day of the results at Stifel, 150 Cheapside, London, EC2V 6ET.

Details of the call will be available on request. The call will be recorded and a replay will be available on Arix's website.

- ENDS -

 

 

For more information, please contact:

 

Arix Bioscience plc

Charlotte Parry, Investor Relations Manager

+44 (0)20 7290 1072

[email protected]

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

[email protected]

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLFFELSRIELIT

Quick facts: Arix Bioscience PLC

Price: 95.74

Market: LSE
Market Cap: £129.78 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19